Press release
Steroid Refactory Acute Graft-Versus-Host Disease Market Set to Grow Substantially Through 2032, DelveInsight Projects | medac GmbH, AltruBio Inc., MaaT Pharma, Incyte Corporation The Steroid Refactory Acute Graft-Versus-Host Disease
DelveInsight's "Steroid Refactory Acute Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Steroid Refactory Acute Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Steroid Refactory Acute Graft-Versus-Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Steroid Refactory Acute Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Steroid Refactory Acute Graft-Versus-Host Disease Market Forecast
https://www.delveinsight.com/sample-request/steroid-refactory-acute-graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Steroid Refactory Acute Graft-Versus-Host Disease Market Report:
• The Steroid Refactory Acute Graft-Versus-Host Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In May 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem TherapiesTM (MET) to improve cancer patient survival through immune modulation, announced that following the EMA Pediatric Committee's approval of its Pediatric Investigation Plan (PIP), the Data and Safety Monitoring Board (DSMB) has completed its final safety review of the pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter European study evaluates the efficacy and safety of MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) involving the gastrointestinal tract, who are receiving third-line treatment after being refractory to steroids and either refractory or intolerant to ruxolitinib.
• In December 2024, The FDA has approved remestemcel-L-rknd (Ryoncil) for treating pediatric patients aged two months and older with steroid-refractory acute graft-versus-host disease (GVHD), according to an agency announcement. The approval is supported by results from the multicenter, prospective, single-arm MSB-GVHD001 trial (NCT02336230), which evaluated the allogeneic bone marrow-derived MSC therapy in 54 children with steroid-refractory acute GVHD following allogeneic hematopoietic stem cell transplantation (HSCT).
• In December 2024, The FDA has granted approval to Mesoblast's allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft-versus-host disease (GvHD) in children aged two months and older.
• The biopsy may help confirm Steroid Refactory Acute Graft-Versus-Host Disease diagnosis, but lacks sensitivity and specificity
• In around 35-50% of patients, aGVHD becomes refractory to systemic steroid therapy
• Key Steroid Refactory Acute Graft-Versus-Host Disease Companies: : MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation, and others
• Key Steroid Refactory Acute Graft-Versus-Host Disease Therapies: MC0518, Neihulizumab, T-Guard, Ruxolitinib, Apraglutide, and others
• The Steroid Refactory Acute Graft-Versus-Host Disease diagnosis is carried through laboratory analysis, imaging, and or endoscopic
Steroid Refactory Acute Graft-Versus-Host Disease Overview
Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) is a serious and life-threatening complication that occurs after an allogeneic stem cell or bone marrow transplant. In this condition, the donated immune cells attack the recipient's body tissues. Normally, steroids are the first line of treatment to control this immune response. However, in steroid-refractory cases, patients either do not respond to steroids or their symptoms worsen, making the disease harder to manage. SR-aGVHD often affects organs such as the skin, liver, and gastrointestinal tract and requires alternative therapies to improve survival and quality of life.
Request a sample for the Steroid Refactory Acute Graft-Versus-Host Disease Market Report:
https://www.delveinsight.com/report-store/steroid-refactory-acute-graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology Segmentation:
The Steroid Refactory Acute Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Steroid Refactory Acute Graft-Versus-Host Disease
• Prevalent Cases of Steroid Refactory Acute Graft-Versus-Host Disease by severity
• Gender-specific Prevalence of Steroid Refactory Acute Graft-Versus-Host Disease
• Diagnosed Cases of Episodic and Chronic Steroid Refactory Acute Graft-Versus-Host Disease
Download the report to understand which factors are driving Steroid Refactory Acute Graft-Versus-Host Disease epidemiology trends @ Steroid Refactory Acute Graft-Versus-Host Disease Epidemiological Insights
https://www.delveinsight.com/sample-request/steroid-refactory-acute-graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Steroid Refactory Acute Graft-Versus-Host Disease Market
The dynamics of the Steroid Refactory Acute Graft-Versus-Host Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Itacitinib, MaaT013, and others during the forecasted period 2019-2032.
Steroid Refactory Acute Graft-Versus-Host Disease Therapies and Emerging Therapies
• MC0518: MaaT Pharma
• Neihulizumab: medac GmbH
• T-Guard: AltruBio Inc
• Ruxolitinib: Incyte Corporation
To know more about Steroid Refactory Acute Graft-Versus-Host Disease treatment, visit @ Steroid Refactory Acute Graft-Versus-Host Disease Medications
https://www.delveinsight.com/sample-request/steroid-refactory-acute-graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Steroid Refactory Acute Graft-Versus-Host Disease Market Drivers
• Rising Incidence of Hematopoietic Stem Cell Transplantation (HSCT)
• High Unmet Medical Need
• Regulatory Support & Designations
• Ongoing Clinical Trials & Emerging Therapies
• Increased Awareness & Diagnosis
Steroid Refactory Acute Graft-Versus-Host Disease Market Barriers
• Complex Pathophysiology
• High Cost of Treatment
• Limited Patient Pool
• Adverse Effects of Therapies
• Delayed Diagnosis and Referral
Scope of the Steroid Refactory Acute Graft-Versus-Host Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Steroid Refactory Acute Graft-Versus-Host Disease Companies: MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation, and others
• Key Steroid Refactory Acute Graft-Versus-Host Disease Therapies: MC0518, Neihulizumab, T-Guard, Ruxolitinib, Apraglutide, and others
• Therapeutic Assessment: Steroid Refactory Acute Graft-Versus-Host Disease current marketed and Steroid Refactory Acute Graft-Versus-Host Disease emerging therapies
• Migraine Market Dynamics: Steroid Refactory Acute Graft-Versus-Host Disease market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Steroid Refactory Acute Graft-Versus-Host Disease Market Access and Reimbursement
Discover more about therapies set to grab major Steroid Refactory Acute Graft-Versus-Host Disease market share @ Steroid Refactory Acute Graft-Versus-Host Disease Treatment Landscape
https://www.delveinsight.com/sample-request/steroid-refactory-acute-graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Steroid Refactory Acute Graft-Versus-Host Disease Market Report Introduction
2. Executive Summary for Steroid Refactory Acute Graft-Versus-Host Disease
3. SWOT analysis of Steroid Refactory Acute Graft-Versus-Host Disease
4. Steroid Refactory Acute Graft-Versus-Host Disease Patient Share (%) Overview at a Glance
5. Steroid Refactory Acute Graft-Versus-Host Disease Market Overview at a Glance
6. Steroid Refactory Acute Graft-Versus-Host Disease Disease Background and Overview
7. Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Steroid Refactory Acute Graft-Versus-Host Disease
9. Steroid Refactory Acute Graft-Versus-Host Disease Current Treatment and Medical Practices
10. Steroid Refactory Acute Graft-Versus-Host Disease Unmet Needs
11. Steroid Refactory Acute Graft-Versus-Host Disease Emerging Therapies
12. Steroid Refactory Acute Graft-Versus-Host Disease Market Outlook
13. Country-Wise Steroid Refactory Acute Graft-Versus-Host Disease Market Analysis (2019-2032)
14. Steroid Refactory Acute Graft-Versus-Host Disease Market Access and Reimbursement of Therapies
15. Steroid Refactory Acute Graft-Versus-Host Disease Market drivers
16. Steroid Refactory Acute Graft-Versus-Host Disease Market barriers
17. Steroid Refactory Acute Graft-Versus-Host Disease Appendix
18. Steroid Refactory Acute Graft-Versus-Host Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Steroid Refactory Acute Graft-Versus-Host Disease Pipeline https://www.delveinsight.com/report-store/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Steroid Refactory Acute Graft-Versus-Host Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Steroid Refactory Acute Graft-Versus-Host Disease market. A detailed picture of the Steroid Refactory Acute Graft-Versus-Host Disease pipeline landscape is provided, which includes the disease overview and Steroid Refactory Acute Graft-Versus-Host Disease treatment guidelines.
Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology https://www.delveinsight.com/report-store/steroid-refactory-acute-graft-versus-host-disease-gvhd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Steroid Refactory Acute Graft-Versus-Host Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports Offered By DelveInsight:
• Addison's Disease Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Cardiac Monitoring System Market: https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
• Medical Sterilization Equipment Market: https://www.delveinsight.com/report-store/medical-sterilization-equipment-market
• Tinnitus Market: https://www.delveinsight.com/report-store/tinnitus-medical-devices-market
• Vutrisiran Market: https://www.delveinsight.com/report-store/vutrisiran-market
• Microscopy Device Market: https://www.delveinsight.com/report-store/microscopy-device-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Steroid Refactory Acute Graft-Versus-Host Disease Market Set to Grow Substantially Through 2032, DelveInsight Projects | medac GmbH, AltruBio Inc., MaaT Pharma, Incyte Corporation The Steroid Refactory Acute Graft-Versus-Host Disease here
News-ID: 4011685 • Views: …
More Releases from DelveInsight Business Research
Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape: DelveInsight …
A comprehensive deep dive into one of oncology's fastest-expanding therapeutic classes covering pipelines, clinical advancements, strategic collaborations, and future-market perspectives
DelveInsight, a prominent market research and strategic consulting company specializing in the life sciences industry, has unveiled its latest intelligence offering, "Antibody-Drug Conjugates (ADCs) - Competitive Landscape, 2025." This extensive report provides a panoramic view of the global ADC space, including detailed evaluations of more than 200 biopharmaceutical companies and 220+…
Atopic Dermatitis Pipeline 2025: FDA Approvals and Clinical Trials Landscape wit …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Ankylosing Spondylitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Diabetic Foot Ulcers Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
